Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data

Charles M. Rudin, John T. Poirier, Lauren Averett Byers, Caroline Dive, Afshin Dowlati, Julie George, John V. Heymach, Jane E Johnson, Jonathan M. Lehman, David MacPherson, Pierre P. Massion, John D Minna, Trudy G. Oliver, Vito Quaranta, Julien Sage, Roman K. Thomas, Christopher R. Vakoc, Adi F Gazdar

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Small cell lung cancer (SCLC) is an exceptionally lethal malignancy for which more effective therapies are urgently needed. Several lines of evidence, from SCLC primary human tumours, patient-derived xenografts, cancer cell lines and genetically engineered mouse models, appear to be converging on a new model of SCLC subtypes defined by differential expression of four key transcription regulators: achaete-scute homologue 1 (ASCL1; also known as ASH1), neurogenic differentiation factor 1 (NeuroD1), yes-associated protein 1 (YAP1) and POU class 2 homeobox 3 (POU2F3). In this Perspectives article, we review and synthesize these recent lines of evidence and propose a working nomenclature for SCLC subtypes defined by relative expression of these four factors. Defining the unique therapeutic vulnerabilities of these subtypes of SCLC should help to focus and accelerate therapeutic research, leading to rationally targeted approaches that may ultimately improve clinical outcomes for patients with this disease.

Original languageEnglish (US)
JournalNature Reviews Cancer
DOIs
StatePublished - Jan 1 2019

Fingerprint

Small Cell Lung Carcinoma
POU Domain Factors
Therapeutic Human Experimentation
Neoplasms
Homeobox Genes
Heterografts
Terminology
Cell Line
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Rudin, C. M., Poirier, J. T., Byers, L. A., Dive, C., Dowlati, A., George, J., ... Gazdar, A. F. (2019). Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nature Reviews Cancer. https://doi.org/10.1038/s41568-019-0133-9

Molecular subtypes of small cell lung cancer : a synthesis of human and mouse model data. / Rudin, Charles M.; Poirier, John T.; Byers, Lauren Averett; Dive, Caroline; Dowlati, Afshin; George, Julie; Heymach, John V.; Johnson, Jane E; Lehman, Jonathan M.; MacPherson, David; Massion, Pierre P.; Minna, John D; Oliver, Trudy G.; Quaranta, Vito; Sage, Julien; Thomas, Roman K.; Vakoc, Christopher R.; Gazdar, Adi F.

In: Nature Reviews Cancer, 01.01.2019.

Research output: Contribution to journalArticle

Rudin, CM, Poirier, JT, Byers, LA, Dive, C, Dowlati, A, George, J, Heymach, JV, Johnson, JE, Lehman, JM, MacPherson, D, Massion, PP, Minna, JD, Oliver, TG, Quaranta, V, Sage, J, Thomas, RK, Vakoc, CR & Gazdar, AF 2019, 'Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data', Nature Reviews Cancer. https://doi.org/10.1038/s41568-019-0133-9
Rudin, Charles M. ; Poirier, John T. ; Byers, Lauren Averett ; Dive, Caroline ; Dowlati, Afshin ; George, Julie ; Heymach, John V. ; Johnson, Jane E ; Lehman, Jonathan M. ; MacPherson, David ; Massion, Pierre P. ; Minna, John D ; Oliver, Trudy G. ; Quaranta, Vito ; Sage, Julien ; Thomas, Roman K. ; Vakoc, Christopher R. ; Gazdar, Adi F. / Molecular subtypes of small cell lung cancer : a synthesis of human and mouse model data. In: Nature Reviews Cancer. 2019.
@article{2c053a29753e4080801c649377409f49,
title = "Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data",
abstract = "Small cell lung cancer (SCLC) is an exceptionally lethal malignancy for which more effective therapies are urgently needed. Several lines of evidence, from SCLC primary human tumours, patient-derived xenografts, cancer cell lines and genetically engineered mouse models, appear to be converging on a new model of SCLC subtypes defined by differential expression of four key transcription regulators: achaete-scute homologue 1 (ASCL1; also known as ASH1), neurogenic differentiation factor 1 (NeuroD1), yes-associated protein 1 (YAP1) and POU class 2 homeobox 3 (POU2F3). In this Perspectives article, we review and synthesize these recent lines of evidence and propose a working nomenclature for SCLC subtypes defined by relative expression of these four factors. Defining the unique therapeutic vulnerabilities of these subtypes of SCLC should help to focus and accelerate therapeutic research, leading to rationally targeted approaches that may ultimately improve clinical outcomes for patients with this disease.",
author = "Rudin, {Charles M.} and Poirier, {John T.} and Byers, {Lauren Averett} and Caroline Dive and Afshin Dowlati and Julie George and Heymach, {John V.} and Johnson, {Jane E} and Lehman, {Jonathan M.} and David MacPherson and Massion, {Pierre P.} and Minna, {John D} and Oliver, {Trudy G.} and Vito Quaranta and Julien Sage and Thomas, {Roman K.} and Vakoc, {Christopher R.} and Gazdar, {Adi F}",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41568-019-0133-9",
language = "English (US)",
journal = "Nature Reviews Cancer",
issn = "1474-175X",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Molecular subtypes of small cell lung cancer

T2 - a synthesis of human and mouse model data

AU - Rudin, Charles M.

AU - Poirier, John T.

AU - Byers, Lauren Averett

AU - Dive, Caroline

AU - Dowlati, Afshin

AU - George, Julie

AU - Heymach, John V.

AU - Johnson, Jane E

AU - Lehman, Jonathan M.

AU - MacPherson, David

AU - Massion, Pierre P.

AU - Minna, John D

AU - Oliver, Trudy G.

AU - Quaranta, Vito

AU - Sage, Julien

AU - Thomas, Roman K.

AU - Vakoc, Christopher R.

AU - Gazdar, Adi F

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Small cell lung cancer (SCLC) is an exceptionally lethal malignancy for which more effective therapies are urgently needed. Several lines of evidence, from SCLC primary human tumours, patient-derived xenografts, cancer cell lines and genetically engineered mouse models, appear to be converging on a new model of SCLC subtypes defined by differential expression of four key transcription regulators: achaete-scute homologue 1 (ASCL1; also known as ASH1), neurogenic differentiation factor 1 (NeuroD1), yes-associated protein 1 (YAP1) and POU class 2 homeobox 3 (POU2F3). In this Perspectives article, we review and synthesize these recent lines of evidence and propose a working nomenclature for SCLC subtypes defined by relative expression of these four factors. Defining the unique therapeutic vulnerabilities of these subtypes of SCLC should help to focus and accelerate therapeutic research, leading to rationally targeted approaches that may ultimately improve clinical outcomes for patients with this disease.

AB - Small cell lung cancer (SCLC) is an exceptionally lethal malignancy for which more effective therapies are urgently needed. Several lines of evidence, from SCLC primary human tumours, patient-derived xenografts, cancer cell lines and genetically engineered mouse models, appear to be converging on a new model of SCLC subtypes defined by differential expression of four key transcription regulators: achaete-scute homologue 1 (ASCL1; also known as ASH1), neurogenic differentiation factor 1 (NeuroD1), yes-associated protein 1 (YAP1) and POU class 2 homeobox 3 (POU2F3). In this Perspectives article, we review and synthesize these recent lines of evidence and propose a working nomenclature for SCLC subtypes defined by relative expression of these four factors. Defining the unique therapeutic vulnerabilities of these subtypes of SCLC should help to focus and accelerate therapeutic research, leading to rationally targeted approaches that may ultimately improve clinical outcomes for patients with this disease.

UR - http://www.scopus.com/inward/record.url?scp=85063913459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063913459&partnerID=8YFLogxK

U2 - 10.1038/s41568-019-0133-9

DO - 10.1038/s41568-019-0133-9

M3 - Article

C2 - 30926931

AN - SCOPUS:85063913459

JO - Nature Reviews Cancer

JF - Nature Reviews Cancer

SN - 1474-175X

ER -